LIVN Stock: Price, Earnings History and SEC Filings
LivaNova PLC (LIVN) last traded at $78.97, down 2.81% on the latest session and up 3.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $1.02 against an analyst estimate of $0.96, a beat of 6.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
LIVN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $1.02 | $0.96 | +6.25% |
| Mar 2026 | May 6, 2026 | $0.87 | $0.72 | +20.83% |
| Dec 2025 | Feb 25, 2026 | $0.73 | $0.67 | +8.96% |
| Sep 2025 | Nov 5, 2025 | $0.97 | $0.78 | +24.36% |
LIVN beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How LIVN reacts to earnings
Across its last 8 earnings releases, LIVN moved 10.6% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | -8.41% |
| 2026-05-06 | Before open | +15.05% |
| 2026-02-25 | Before open | +1.80% |
| 2025-11-05 | Before open | -5.80% |
| 2025-08-06 | Before open | +11.15% |
| 2025-05-07 | Before open | +23.72% |
| 2025-02-25 | Before open | -15.76% |
| 2024-10-30 | Before open | -3.08% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
LIVN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1.4B | -$242M | $173M | -17.5% | $-4.45 |
| 2024 | $1.3B | $63M | $136M | 5.0% | $1.16 |
| 2023 | $1.2B | $18M | $40M | 1.5% | $0.32 |
| 2022 | $1.0B | -$86M | $43M | -8.4% | $-1.61 |
| 2021 | $1.0B | -$136M | $77M | -13.1% | $-2.68 |
| 2020 | $934M | -$349M | -$114M | -37.3% | $-7.18 |
| 2019 | $1.1B | -$158M | -$116M | -14.5% | $-3.26 |
| 2018 | $1.1B | -$189M | $83M | -17.1% | $-3.91 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for LIVN
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 11, 2026Shareholder vote, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 29, 2026
- 10-K · Feb 25, 2026
- 8-K · Feb 25, 2026Results of operations, Financial statements and exhibits
- 8-K · Jan 14, 2026Officer or director change
- 10-Q · Nov 5, 2025
Insider filing activity
LIVN insiders filed 5 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
LIVN news
- ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue EstimatesOct 28, 2026 · finance.yahoo.com
- Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant EpilepsyOct 23, 2026 · finance.yahoo.com
- LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in NovemberOct 21, 2026 · finance.yahoo.com
- Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of DirectorsOct 20, 2026 · finance.yahoo.com
About LivaNova PLC
LivaNova PLC (LIVN) is a US-listed public company on Nasdaq. The SEC classifies its business as Electromedical & Electrotherapeutic Apparatus. It is incorporated in United Kingdom. Its fiscal year ends in December.